Camibirstat

DB21586InvestigationalSmall molecule

Camibirstat is a small molecule drug. Camibirstat is under investigation in clinical trial NCT04891757 (FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies). Camibirstat has a monoisotopic...

Mechanism: Pharmacologically active on SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 and SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2
Curator reviewed
Formula / weight: C₂₄H₃₀N₆O₆S₂ · 562.66 g/mol (avg)
Code names: FHD-286

Resolves to

Compound

UNIIQHA5XLA4SACAS2671128-05-3ChEMBLCHEMBL5095181

Structure

InChIKeyJBLQNFBXKOAIHG-FCEWJHQRSA-NSMILESCOC[C@H](NC(=O)C1=CN(C=C1)S(C)(=O)=O)C(=O)NC1=NC(=CS1)C1=NC(=CC=C1)N1C[C@H](C)O[C@H](C)C1

Targets

P51532SMARCA4P51531SMARCA2

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Camibirstat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account